, Tracking Stock Market Picks
Enter Symbol:
Rating: LRP
Neutral $4

Aptose Biosciences Inc. (NASDAQ: APTO) downgraded to Neutral with price target $4 by Roth Capital

Friday,  Nov 20, 2015  11:25 AM ET by Lynn Gilbert

Roth Capital downgraded Aptose Biosciences Inc. (NASDAQ: APTO) to Neutral with price
target $4. Previously, Roth Capital rated Aptose Biosciences Inc. (NASDAQ: APTO) to Buy on 02/13/2014, when the stock price was valued at $0.68.

Lorus Therapeutics is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in- licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy